title: Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
abstract: Surgical bypass of peripheral arterial occlusive disease with autologous vein grafts provides an effective means of restoring blood flow to the lower extremity, and has been a standard therapy for patients with disabling claudication or critical limb ischemia (CLI). However, failure rates may run as high as 50% within 5 years. These graft failures occur as a result of neointimal hyperplasia, a ubiquitous biologic response of blood vessel walls to injury, which is characterized by the migration and proliferation of smooth muscle cells (SMC). The E2F family of transcription factors regulates the expression of genes controlling SMC proliferation. Edifoligide (E2F Decoy) is a novel therapy that inhibits E2F function, thus attenuating neointimal hyperplasia. Its use in conjunction with a patented drug delivery pressurization chamber is under investigation. Using this system, edifoligide is administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation, resulting in minimal systemic drug exposure and excellent patient compliance. This Phase 3, randomized, double-blind, multicenter clinical trial is designed to evaluate the safety and efficacy of edifoligide in a population of approximately 1400 patients with CLI undergoing infrainguinal bypass for peripheral arterial disease (PAD). The primary outcome measure will be the time to occurrence of non-technical graft failure resulting in either graft revision or major amputation at 12 months after enrollment. A governing Clinical Events Classification committee (CEC) will adjudicate each graft failure to determine its etiology. The PREVENT III trial is the largest multicenter trial ever performed in patients receiving autologous vein bypass grafts for CLI. This landmark study will determine if edifoligide is safe and effective at preventing vein graft failure in patients undergoing lower extremity bypass, but it also provides a unique opportunity to observe current treatment practices in vascular surgery.
authors.affiliation: Division of Vascular Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA. mconte@partners.org
authors.forename: Michael S
authors.initials: MS
authors.lastname: Conte
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Lorenz
authors.forename: Dennis F
authors.initials: DF
authors.lastname: Bandyk
authors.forename: Alexander W
authors.initials: AW
authors.lastname: Clowes
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Moneta
authors.forename: B Lynn
authors.initials: BL
authors.lastname: Seely
mesh_terms: D001157:Arterial Occlusive Diseases / Q000601:surgery; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D017326:Clinical Trials, Phase III as Topic; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D050684:E2F Transcription Factors; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009841:Oligonucleotides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D014680:Veins / Q000187:drug effects
chemical_list: D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D009841:Oligonucleotides; D014157:Transcription Factors; C502518:edifoligide